Cardiomyopathy and arrhythmia are significant cardiovascular disorders that affect the heart’s structure and function. Cardiomyopathy refers to diseases of the heart muscle, which can lead to diminished cardiac output and potentially heart failure; the condition manifests in various forms such as dilated, hypertrophic, and restrictive cardiomyopathy. Arrhythmia, on the other hand, involves irregularities in the heart’s rhythm, ranging from benign premature beats to potentially life-threatening conditions like atrial fibrillation or ventricular tachycardia. Both disorders can be congenital or acquired, stemming from genetic mutations, lifestyle factors, or underlying medical conditions. They significantly impact heart function and overall health, requiring careful diagnosis and management to prevent serious complications such as stroke, sudden cardiac arrest, or progressive heart failure.
What is the Program?
Ensure your patients have options to access genetic testing through our new genetic testing program.
– 1 in 5 patients with a suspected genetic cardiomyopathy or arrhythmia have a positive genetic test result.1
– 2 in 3 of those positive results confer clinical management implications, including targeted therapy or increased risk.1
– ~11% of patients who may have been missed using condition-specific panels were captured with comprehensive testing (like that featured in the Invitae Unlock™ program).2
Available to individuals in the United States suspected of having a familial cardiomyopathy or arrhythmia.
*Note that postmortem testing is not available through this program.
Order a blood, buccal or saliva collection kit.
Invitae (OTC: NVTA) is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We aim to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae’s genetics experts apply a rigorous approach to data and research, serving as the foundation of their mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.
To learn more, visit invitae.com and follow for updates on LinkedIn, X, Instagram, and Facebook @Invitae.
1. Callis TE, et al. Precision medicine opportunities for familial arrhythmias and cardiomyopathies identified when cost of genetic testing is removed as a barrier. J Am Coll Cardiol. 2020;75(11)(suppl1):1-5.
2. Dellefave-Castillo LM et al. Combined cardiomyopathy and arrhythmia genetic testing identifies clinical management implications and unexpected results. Presented at: American Heart Association Scientific Sessions; Nov. 13-15, 2021 (virtual meeting).
